Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May 15;25(8):1123-6.
doi: 10.1097/QAD.0b013e328346269f.

Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance

Ujjwal Neogi  1 , Anita Shet, Ranjani Shamsundar, Maria L Ekstrand
Affiliations

Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance

Ujjwal Neogi et al. AIDS. .

Abstract

Prevalence of etravirine genotypic resistance was assessed among 92 HIV-1C-infected patients failing nevirapine and efavirenz-based regimens from a cohort of 552 Indian patients. Overall, prevalence of etravirine cross-resistance identified using the Tibotec Weighted Score was 41% (31.5% intermediately-resistant and 9.8% fully-resistant). The most frequently described nonnucleoside reverse transcriptase inhibitor-associated mutations included Y181 (35.9%), K101 (20.7%), G190 (17.4%), and V108 (15.2%). The resistant group demonstrated higher viral load (P = 0.01) and longer duration of antiretroviral treatment (P = 0.03) compared with the susceptible group.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Selection of NNRTI mutations in ART experienced patients harboring HIV-1 subtype C viruses
Higher frequencies of NNRTI drug resistance mutations are present in residues Y181, K101, G190 and V108 in Indian sequences (n=521, 92 primary isolates and 429 previously reported sequences) compared to global subtype C sequences (n=1122) obtained from HIVseq Program from Stanford University HIV Drug resistance database (http://hivdb.stanford.edu/; accessed on 13th August 2010).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Joly V, Yeni P. Non-nucleoside reverse transcriptase inhibitors. Ann Med Interne (Paris) 2000;151:260–267. - PubMed
    1. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38. - PubMed
    1. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39–48. - PubMed
    1. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. Update of the Drug Resistance Mutations in HIV-1. Top HIV Med. 2008;16:138–45. - PubMed
    1. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 2010;24:503–14. - PubMed